![Marc Rogers](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marc Rogers
Keine laufenden Positionen mehr
Karriereverlauf von Marc Rogers
Ehemalige bekannte Positionen von Marc Rogers
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Metrion Biosciences Ltd.
![]() Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Direktor/Vorstandsmitglied | - | 20.12.2023 |
Technik-/Wissenschafts-/F&E-Leiter | - | - |
Statistik
International
Vereinigtes Königreich | 2 |
Operativ
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Metrion Biosciences Ltd.
![]() Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Health Technology |
- Börse
- Insiders
- Marc Rogers
- Erfahrung